Adagio Medical Holdings, Inc.
Adagio Medical Holdings, Inc. is an emerging medical device firm focused on pioneering and commercializing innovative ablation technologies. Its core mission is to provide therapeutic solutions for various cardiac rhythm disorders, including but not limited to atrial fibrillation, atrial flutter, and ventricular…
1D
-3.9%
1W
-23.8%
1M
-80.2%
6M
-93.6%
YTD
-90.5%
1Y
-93.3%
2Y
-96.6%
5Y
–
10Y
–
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~57% weaker price swings than usual
PRICE TARGET LOW
US$3.00
CONSENSUS
US$3.00
MEDIAN
US$3.00
PRICE TARGET HIGH
US$3.00
No current analyst ratings available.
P/E
-0.07
P/B
-5.3
EV/EBITDA
-0.88
RETURN ON EQUITY
1,618.6%
NET MARGIN
0.0%
DEBT/EQUITY
-62.65
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
FREE FLOAT
98.2%
FLOAT SHARES
21,800,738
AVG. DAILY VOLUME (30D)
3,311,560
Mirsaeedi-Farahani Keyvan
Adagio Medical Holdings, Inc. is a company in the Healthcare sector, Medical - Devices industry, headquartered in United States.
The CEO is Todd Usen, the company employs around 41 people.
The IPO was on 01/08/2024; the stock trades on NASDAQ under the ticker ADGM.
The average price target is US$3.00, ranging from US$3.00 to US$3.00, with a median of US$3.00.
This is an external assessment, not a statement by Market Jury.
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly -57% stronger than usual.
No, Adagio Medical Holdings currently does not pay a dividend.
Comparable stocks include Abbott Laboratories, Stryker, Boston Scientific, Edwards Lifesciences, DexCom, GE HealthCare Technologies, Zimmer Biomet Holdings and Align Technology.
Clicking "Analyze stock" lets five strategies assess Adagio Medical Holdings against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.